Recent news on Miconazole Nitrate

Barrier Therapeutics to Present at the Bank of America 2007 Health ...  -  May 24, 2007
WM Experts (press release),Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis;

Barrier Therapeutics to Present at the 2007 Morgan Stanley Global ...  -  26 Apr 2007
Market Wire (press release)Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis;

Barrier Therapeutics to Present at the CIBC World Markets Annual ...  -  Apr 5, 2007
Web Services Journal,Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis;

Barrier Therapeutics Announces Agreement to Co-Promote Vusion ...  -  Mar 6, 2007
PharmaLive.com (press release),...will promote Barrier Therapeutics' VusionT (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment to pediatricians in the US

Barrier Therapeutics Receives Regulatory Approval to Market ...  -  Mar 8, 2007
Genetic Engineering News (press release),Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis;

Barrier Therapeutics to Present at the SIGnificant Investment ...  -  Feb 22, 2007
SYS-CON Media,Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis;

Barrier Therapeutics to Release Fourth Quarter and Full Year 2006 ...  -  Feb 22, 2007
Genetic Engineering News (press release),Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis;

American Academy Of Dermatology: Dermatologists Offer Top Tips For ...  -  Feb 3, 2007
Medical News Today (press release),In 2006, the FDA approved a new ointment for treating diaper dermatitis associated with candida that contains 0.25 percent miconazole nitrate in a base of

SEC Charges Family with Insider Trading Scheme  -  Feb 13, 2007
CCH Wall Street,For example, Zvi Rosenthal became aware of an impeding FDA approval of a new Taro product, Miconazole Nitrate Vaginal Cream, during a company meeting on

Barrier Therapeutics Announces Positive Phase 2a Data for Oral ...  -  18 Jan 2007
PipelineReview.com (press release),...for seborrheic dermatitis; Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by

Barrier Therapeutics to Present at the 25th Annual JPMorgan ...  -  Jan 3, 2007
Market Wire (press release)2%, for seborrheic dermatitis; Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated

Barrier Therapeutics to Participate in the 2006 RBC Capital ...  -  Dec 6, 2006
Genetic Engineering News (press release),Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution.

Barrier Therapeutics to Present at the Susquehanna Emerging Trends ...  Oct 25, 2006
...currently markets three pharmaceutical products in the United States: Xolegel™ (ketoconazole, USP) Gel, 2%, Vusion™ (0.25% miconazole nitrate, 15% zinc ... -Market Wire (press release) Barrier Therapeutics Announces Third Quarter 2006 Financial ...  Oct 31, 2006
...currently markets three pharmaceutical products in the United States: Xolegel(TM) (ketoconazole, USP) Gel, 2%, Vusion(TM) (0.25% miconazole nitrate, 15% zinc ... -Genetic Engineering News (press release), Barrier Therapeutics to Present at the UBS Global Life Sciences ...  Sep 19, 2006
...currently markets three pharmaceutical products in the United States: Xolegel™ (ketoconazole, USP) Gel, 2%, Vusion™ (0.25% miconazole nitrate, 15% zinc ... -Market Wire

Barrier Therapeutics, Inc. to Raise $25 Million in Registered ...  Sep 15, 2006
...currently markets three pharmaceutical products in the United States: Xolegel(TM) (ketoconazole, USP) Gel, 2%, Vusion(TM) (0.25% miconazole nitrate, 15% zinc ... -Genetic Engineering News

Barrier Therapeutics to Participate in the 2006 RBC Capital ...  -  Dec 6, 2006
Genetic Engineering News (press release),Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution.

Barrier Therapeutics Launches Denavir(R) in Canada  Aug 23, 2006
...currently markets three pharmaceutical products in the United States: Xolegel™ (ketoconazole, USP) Gel, 2%, Vusion™ (0.25% miconazole nitrate, 15% zinc ... -Market Wire

Barrier Therapeutics Launches Denavir in Canada  Aug 23, 2006
...currently markets three pharmaceutical products in the United States: Xolegel TM (ketoconazole, USP) Gel, 2%, Vusion TM (0.25% miconazole nitrate, 15% zinc ... -CCNMatthews

Barrier Therapeutics Receives FDA Approval of Xolegel(TM) Gel for ...  Jul 28, 2006
...this year and will be the Company's third marketed product in the US In February, Barrier received approval for Vusion™ (0.25% miconazole nitrate, 15% zinc ... -Market Wire

Barrier Therapeutics Announces Second Quarter 2006 Financial ...  Aug 7, 2006
April 2006, we expanded our US sales organization from 21 to 60 sales associates in support of the launch of the Vusion™ (0.25% miconazole nitrate, 15% zinc ... -Market Wire

Barrier Therapeutics to Present Data on Solagé(R) and Sebazole(TM ...  Jul 27, 2006
The Company currently markets two pharmaceutical products in the United States, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, and 81.35% white petrolatum ... -Market Wire

Barrier Therapeutics to Present at the CE Unterberg, Towbin ...  Jul 5, 2006
The Company currently markets two pharmaceutical products in the United States, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, and 81.35% white petrolatum ... -Market Wire



Barrier Therapeutics to Present at Bank of America 2006 Health ...  May 10, 2006
The Company currently markets two pharmaceutical products in the United States, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, and 81.35% white petrolatum ... - Market Wire

Barrier Therapeutics Announces First Quarter 2006 Financial ...  May 2, 2006
Approval by the US Food and Drug Administration of Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment for the treatment ... - Market Wire





Barrier Therapeutics to Present at CIBC World Markets Annual ...  Mar 29, 2006
The Company currently markets two pharmaceutical products in the United States, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, and 81.35% white petrolatum ... - Market Wire

Barrier Therapeutics Acquires the Canadian Distribution Rights For ...  Mar 15, 2006
In the US, Barrier markets Vusion ™ (0.25% miconazole nitrate, 15% zinc oxide and 81.35% white petrolatum) Ointment for the treatment of diaper dermatitis ... - PharmaLive.com

Mochida Health Care to Launch New Dandruff Shampoo  Mar 9, 2006
The new product, which contains miconazole nitrate as an active ingredient, inhibits the propagation of bacteria and prevents dandruff and itchy scalp. ... - Japan Corporate News



Barrier Therapeutics Announces Fourth Quarter and Year End 2005 ...  Feb 27, 2006
Approval by the US Food and Drug Administration, FDA, of Vusion (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment for the ... - Market Wire

Barrier Therapeutics to Release Fourth Quarter and Year-End 2005 ...  Feb 21, 2006
In addition to Vusion™ (0.25% miconazole nitrate, 15% zinc oxide and 81.35% white petrolatum) Ointment, which recently received FDA approval for the ... - Market Wire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional